Sadelain, Michel

Publications

Sort by

Co-Author Network

selected publications

Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma. 2024 GET IT
Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell. 2024 Academic Article GET IT
GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Molecular therapy : the journal of the American Society of Gene Therapy. 2024 Academic Article GET IT
Engineering immune-evasive allogeneic cellular immunotherapies. Nature reviews. Immunology. 2024 Review GET IT
Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. 2024 GET IT
Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness. 2024 GET IT
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies. Nature cancer. 2024 Academic Article GET IT
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit. 2024 GET IT
Author Correction: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. 2024 GET IT
Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies. 2024 GET IT
Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. 2024 GET IT
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nature aging. 2024 Academic Article GET IT
Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function. Cancer discovery. 2023 Academic Article GET IT
Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells. 2023 GET IT
Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer cell. 2023 Academic Article GET IT
CAR T cell design: approaching the elusive AND-gate. Cell research. 2023 Comment GET IT
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. 2023 GET IT
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nature medicine. 2023 Academic Article GET IT
Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. Haematologica. 2023 Editorial Article GET IT
Times cited: 5
Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology. The Journal of molecular diagnostics : JMD. 2023 Academic Article GET IT
Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood. 2023 Academic Article GET IT
Times cited: 16
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Academic Article GET IT
Times cited: 389
Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer discovery. 2023 Academic Article GET IT
Times cited: 40
CD19 CAR antigen engagement mechanisms and affinity tuning. Science immunology. 2023 Academic Article GET IT
TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature. 2023 Academic Article GET IT
Times cited: 54
The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2022 Academic Article GET IT
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. 2022 GET IT
Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature biomedical engineering. 2022 Academic Article GET IT
Times cited: 43
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022 Academic Article GET IT
Times cited: 93
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature medicine. 2022 Academic Article GET IT
Times cited: 142
Globin vector regulatory elements are active in early hematopoietic progenitor cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2022 Academic Article GET IT
Times cited: 1
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 26
HLA-independent T cell receptors for targeting tumors with low antigen density. Nature medicine. 2022 Academic Article GET IT
Times cited: 88
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Nature medicine. 2022 Academic Article GET IT
Times cited: 27
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science translational medicine. 2021 Academic Article GET IT
Times cited: 60
Ectopic activation of the miR-200c-EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Science translational medicine. 2021 Academic Article GET IT
Times cited: 7
Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021 Academic Article GET IT
Times cited: 45
CAR T cells: Building on the CD19 paradigm. European journal of immunology. 2021 Review GET IT
Times cited: 40
Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease. Blood cells, molecules & diseases. 2021 Academic Article GET IT
Times cited: 3
Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells. Small methods. 2021 Academic Article GET IT
Times cited: 15
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature reviews. Immunology. 2021 Review GET IT
Times cited: 441
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021 Academic Article GET IT
Times cited: 25
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors. Immuno-oncology technology. 2020 Review GET IT
Times cited: 13
Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020 Academic Article GET IT
Times cited: 578
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. British journal of haematology. 2020 Academic Article GET IT
Times cited: 53
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 Academic Article GET IT
Times cited: 199
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science translational medicine. 2019 Academic Article GET IT
Times cited: 356
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 60
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone marrow transplantation. 2019 Academic Article GET IT
Times cited: 92
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 122
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI insight. 2019 Academic Article GET IT
Times cited: 80
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019 Academic Article GET IT
Times cited: 432
Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. 2019 GET IT
Times cited: 6
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 80
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature medicine. 2018 Academic Article GET IT
Times cited: 340
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 188
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. Molecular therapy. Methods & clinical development. 2018 Academic Article GET IT
Times cited: 23
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Academic Article GET IT
Times cited: 207
Chimeric Antigen Receptor Therapy. The New England journal of medicine. 2018 Review GET IT
Times cited: 1505
Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia. Trends in molecular medicine. 2018 Comment GET IT
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2018 Academic Article GET IT
Times cited: 227
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 64
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 45
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 638
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature medicine. 2018 Academic Article GET IT
Times cited: 914
Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Information Resource GET IT
Times cited: 9
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1948
Safety and efficacy of plerixafor dose escalation for the mobilization of CD34⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018 Academic Article GET IT
Times cited: 51
Posttransplant chimeric antigen receptor therapy. Blood. 2018 Information Resource GET IT
Times cited: 69
Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 171
Gene therapy comes of age. Science (New York, N.Y.). 2018 Review GET IT
Times cited: 779
Gene Therapy and Genome Editing. Hematology/oncology clinics of North America. 2018 Review GET IT
Times cited: 21
CD19 CAR T Cells. Cell. 2017 Academic Article GET IT
Times cited: 75
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 6
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Information Resource GET IT
Times cited: 40
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer cell. 2017 Academic Article GET IT
Times cited: 228
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. Oncotarget. 2017 Academic Article GET IT
Times cited: 30
Therapeutic T cell engineering. Nature. 2017 Review GET IT
Times cited: 638
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Molecular therapy : the journal of the American Society of Gene Therapy. 2017 Information Resource GET IT
Times cited: 79
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017 Academic Article GET IT
Times cited: 1288
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Molecular therapy oncolytics. 2017 Academic Article GET IT
Times cited: 69
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nature medicine. 2017 Academic Article GET IT
Times cited: 176
LiPS-A3S, a human genomic site for robust expression of inserted transgenes. Molecular therapy. Nucleic acids. 2016 Academic Article GET IT
Times cited: 1
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 232
Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8⁺ T cells for adoptive immunotherapy of cancer and infections. Clinical and experimental immunology. 2016 Academic Article GET IT
Times cited: 31
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Translational cancer research. 2016 Comment GET IT
Times cited: 20
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 802
Chimeric antigen receptors: driving immunology towards synthetic biology. Current opinion in immunology. 2016 Information Resource GET IT
Times cited: 75
Biology and clinical application of CAR T cells for B cell malignancies. International journal of hematology. 2016 Information Resource GET IT
Times cited: 60
Tales of Antigen Evasion from CAR Therapy. Cancer immunology research. 2016 Comment GET IT
Times cited: 6
Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response. Trends in molecular medicine. 2016 Comment GET IT
Times cited: 11
A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome Editing. Molecular therapy : the journal of the American Society of Gene Therapy. 2016 Editorial Article GET IT
Times cited: 1
Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene. Molecular therapy. Nucleic acids. 2016 Academic Article GET IT
Times cited: 9
MicroRNA-27b Enhances the Hepatic Regenerative Properties of Adipose-Derived Mesenchymal Stem Cells. Molecular therapy. Nucleic acids. 2016 Academic Article GET IT
Times cited: 15
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer discovery. 2015 Information Resource GET IT
Times cited: 366
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer cell. 2015 Academic Article GET IT
Times cited: 626
CAR therapy: the CD19 paradigm. The Journal of clinical investigation. 2015 Information Resource GET IT
Times cited: 193
The pharmacology of second-generation chimeric antigen receptors. Nature reviews. Drug discovery. 2015 Information Resource GET IT
Times cited: 417
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PloS one. 2015 Academic Article GET IT
Times cited: 57
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015 Academic Article GET IT
Times cited: 42
Genome editing technologies: defining a path to clinic. Molecular therapy : the journal of the American Society of Gene Therapy. 2015 Conference Paper GET IT
Times cited: 94
The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer cell. 2015 Information Resource GET IT
Times cited: 120
New cell sources for T cell engineering and adoptive immunotherapy. Cell stem cell. 2015 Information Resource GET IT
Times cited: 138
Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. Journal of immunotherapy (Hagerstown, Md. : 1997). 2015 Academic Article GET IT
Times cited: 60
The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. Stem cell reports. 2015 Academic Article GET IT
Times cited: 5
CD19 CAR Therapy for Acute Lymphoblastic Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Information Resource GET IT
Times cited: 32
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Science translational medicine. 2014 Academic Article GET IT
Times cited: 449
A cell engineering strategy to enhance the safety of stem cell therapies. Cell reports. 2014 Academic Article GET IT
Times cited: 11
T-cell immunotherapy: looking forward. Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Conference Paper GET IT
Times cited: 56
From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction. Cancer journal (Sudbury, Mass.). 2014 Editorial Article GET IT
Times cited: 2
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 2067
Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints. Virology journal. 2014 Academic Article GET IT
Times cited: 7
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014 Academic Article GET IT
Times cited: 58
Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 134
Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing. Journal of virology. 2013 Academic Article GET IT
Times cited: 10
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science translational medicine. 2013 Academic Article GET IT
Times cited: 595
Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 21
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nature biotechnology. 2013 Academic Article GET IT
Times cited: 363
Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure. PloS one. 2013 Academic Article GET IT
Times cited: 20
CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Biochemical and biophysical research communications. 2013 Academic Article GET IT
Times cited: 18
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer research. 2013 Academic Article GET IT
Times cited: 10
High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. Journal of virology. 2013 Academic Article GET IT
Times cited: 32
Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 22
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PloS one. 2013 Academic Article GET IT
Times cited: 151
The basic principles of chimeric antigen receptor design. Cancer discovery. 2013 Information Resource GET IT
Times cited: 1112
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine. 2013 Academic Article GET IT
Times cited: 1711
Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 174
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature biotechnology. 2012 Academic Article GET IT
Times cited: 732
How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012 Academic Article GET IT
Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. Blood. 2012 Academic Article GET IT
Times cited: 65
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 161
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 Academic Article GET IT
Times cited: 569
The potential of stem cells as an in vitro source of red blood cells for transfusion. Cell stem cell. 2012 Information Resource GET IT
Times cited: 60
Safe harbours for the integration of new DNA in the human genome. Nature reviews. Cancer. 2011 Information Resource GET IT
Times cited: 265
Hematopoietic stem cell engineering at a crossroads. Blood. 2011 Information Resource GET IT
Times cited: 65
Eliminating cells gone astray. The New England journal of medicine. 2011 Editorial Article GET IT
Times cited: 9
An in vivo platform for tumor biomarker assessment. PloS one. 2011 Academic Article GET IT
Times cited: 17
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer immunology, immunotherapy : CII. 2011 Information Resource GET IT
Times cited: 43
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Academic Article GET IT
Times cited: 1119
Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice. Stem cells international. 2011 Academic Article GET IT
Times cited: 13
Tolerance induction by allogeneic hematopoietic stem cells. Cell stem cell. 2011 Comment GET IT
Times cited: 3
Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites. Nature protocols. 2011 Academic Article GET IT
Times cited: 12
Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector. Nature protocols. 2011 Academic Article GET IT
Times cited: 54
Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer immunology, immunotherapy : CII. 2011 Academic Article GET IT
Times cited: 66
Genetic strategies for the treatment of sickle cell anaemia. British journal of haematology. 2011 Information Resource GET IT
Times cited: 7
miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell stem cell. 2011 Academic Article GET IT
Times cited: 100
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer research. 2011 Academic Article GET IT
Times cited: 84
A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic acids research. 2011 Academic Article GET IT
Times cited: 66
CARs on track in the clinic. Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Conference Paper GET IT
Times cited: 108
Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nature biotechnology. 2010 Academic Article GET IT
Times cited: 263
The need for genetically engineering therapeutic pluripotent stem cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Editorial Article GET IT
Times cited: 4
RORing T cells target CLL and MCL. Blood. 2010 Article GET IT
Benefits of utilizing gene-modified iPSCs for clinical applications. Cell stem cell. 2010 Letter GET IT
Times cited: 19
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 57
Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 371
Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. Blood. 2010 Academic Article GET IT
Times cited: 37
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. Journal of immunological methods. 2010 Academic Article GET IT
Times cited: 9
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Letter GET IT
Times cited: 342
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010 Academic Article GET IT
Times cited: 180
A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem cells (Dayton, Ohio). 2010 Academic Article GET IT
Times cited: 67
Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies. Discovery medicine. 2009 Information Resource GET IT
Times cited: 6
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 256
T-cell engineering for cancer immunotherapy. Cancer journal (Sudbury, Mass.). 2009 Information Resource GET IT
Times cited: 35
Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2009 Information Resource GET IT
Times cited: 10
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Molecular therapy : the journal of the American Society of Gene Therapy. 2009 Academic Article GET IT
Times cited: 437
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009 Academic Article GET IT
Times cited: 741
A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 28
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. The Prostate. 2009 Academic Article GET IT
Times cited: 61
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 239
Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Human gene therapy. 2009 Academic Article GET IT
Times cited: 10
The promise and potential pitfalls of chimeric antigen receptors. Current opinion in immunology. 2009 Information Resource GET IT
Times cited: 400
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nature biotechnology. 2009 Academic Article GET IT
Times cited: 2749
Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nature medicine. 2009 Academic Article GET IT
Times cited: 109
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009 Academic Article GET IT
Times cited: 253
Retroviral transduction of murine primary T lymphocytes. Methods in molecular biology (Clifton, N.J.). 2009 Academic Article GET IT
Times cited: 36
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. The Journal of clinical investigation. 2008 Academic Article GET IT
Times cited: 56
Stem cell engineering for the treatment of severe hemoglobinopathies. Current molecular medicine. 2008 Information Resource GET IT
Times cited: 24
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 31
Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes. Gene therapy. 2008 Academic Article GET IT
Times cited: 2
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008 Academic Article GET IT
Times cited: 80
A "vector drain" in US gene therapy development?. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Editorial Article GET IT
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature biotechnology. 2008 Academic Article GET IT
Times cited: 104
In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. Cancer research. 2007 Academic Article GET IT
Times cited: 61
Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Human gene therapy. 2007 Academic Article GET IT
Times cited: 30
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature medicine. 2007 Academic Article GET IT
Times cited: 208
Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood. 2007 Academic Article GET IT
Times cited: 49
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 306
Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications. Journal of immunotherapy (Hagerstown, Md. : 1997). 2007 Academic Article GET IT
Times cited: 6
Fetal gene therapy of alpha-thalassemia in a mouse model. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 34
Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. Vaccine. 2007 Academic Article GET IT
Times cited: 27
The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Molecular therapy : the journal of the American Society of Gene Therapy. 2007 Information Resource GET IT
Times cited: 71
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Human gene therapy. 2007 Review GET IT
Times cited: 40
Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nature biotechnology. 2006 Academic Article GET IT
Times cited: 69
Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Human gene therapy. 2006 Academic Article GET IT
Times cited: 8
Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Current opinion in hematology. 2006 Information Resource GET IT
Times cited: 42
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. European journal of nuclear medicine and molecular imaging. 2006 Academic Article GET IT
Times cited: 27
Cutting Edge: CD28 controls dominant regulatory T cell activity during active immunization. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 13
Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 6
Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Experimental hematology. 2006 Academic Article GET IT
Times cited: 29
The meaning of translation. Cancer investigation. 2006 Editorial Article GET IT
Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene therapy. 2006 Academic Article GET IT
Times cited: 23
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature biotechnology. 2005 Academic Article GET IT
Times cited: 96
Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer research. 2005 Academic Article GET IT
Times cited: 94
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. International journal of cancer. 2005 Academic Article GET IT
Times cited: 50
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2005 Academic Article GET IT
Times cited: 197
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer research. 2005 Academic Article GET IT
Times cited: 51
Fulminant experimental autoimmune encephalo-myelitis induced by retrovirally mediated TCR gene transfer. European journal of immunology. 2005 Academic Article GET IT
Times cited: 4
Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 2005 Academic Article GET IT
Times cited: 166
Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses. Journal of immunology (Baltimore, Md. : 1950). 2005 Academic Article GET IT
Times cited: 17
Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. Best practice & research. Clinical haematology. 2004 Information Resource GET IT
Times cited: 20
Ligand binding to inhibitory killer cell Ig-like receptors induce colocalization with Src homology domain 2-containing protein tyrosine phosphatase 1 and interruption of ongoing activation signals. Journal of immunology (Baltimore, Md. : 1950). 2004 Academic Article GET IT
Times cited: 28
Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Current hematology reports. 2004 Information Resource GET IT
Times cited: 17
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Academic Article GET IT
Times cited: 107
Insertional oncogenesis in gene therapy: how much of a risk?. Gene therapy. 2004 Academic Article GET IT
Times cited: 66
The ABCs of artificial antigen presentation. Nature biotechnology. 2004 Information Resource GET IT
Times cited: 142
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular therapy : the journal of the American Society of Gene Therapy. 2003 Information Resource GET IT
Times cited: 136
Occurrence of leukaemia following gene therapy of X-linked SCID. Nature reviews. Cancer. 2003 Information Resource GET IT
Times cited: 290
Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood. 2003 Academic Article GET IT
Times cited: 56
Development of a new reporter gene system--dsRed/xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier. Molecular imaging. 2003 Academic Article GET IT
Times cited: 33
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 266
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nature biotechnology. 2003 Academic Article GET IT
Times cited: 197
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature medicine. 2003 Academic Article GET IT
Times cited: 468
Targeting tumours with genetically enhanced T lymphocytes. Nature reviews. Cancer. 2003 Information Resource GET IT
Times cited: 365
A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood. 2002 Academic Article GET IT
Times cited: 183
Therapeutic globin gene delivery using lentiviral vectors. Current opinion in molecular therapeutics. 2002 Information Resource GET IT
Times cited: 21
Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene. 2002 Academic Article GET IT
Times cited: 62
Sturm und drang over suicidal lymphocytes. Molecular therapy : the journal of the American Society of Gene Therapy. 2002 Information Resource GET IT
Times cited: 12
Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. Cancer research. 2002 Academic Article GET IT
Times cited: 38
Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002 Academic Article GET IT
Times cited: 145
Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapy. The journal of gene medicine. 2002 Information Resource GET IT
Times cited: 11
Frequency of missense mutations in the coding region of a eukaryotic gene transferred by retroviral vectors. Journal of virology. 2002 Academic Article GET IT
Times cited: 5
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nature biotechnology. 2002 Academic Article GET IT
Times cited: 592
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (New York, N.Y.). 2001 Academic Article GET IT
Times cited: 160
A promising genetic approach to the treatment of beta-thalassemia. Trends in cardiovascular medicine. 2001 Information Resource GET IT
Times cited: 12
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 205
Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. Gene. 2001 Academic Article GET IT
Times cited: 6
Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Molecular therapy : the journal of the American Society of Gene Therapy. 2001 Academic Article GET IT
Times cited: 39
Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood. 2001 Academic Article GET IT
Times cited: 127
Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. Journal of immunology (Baltimore, Md. : 1950). 2001 Academic Article GET IT
Times cited: 91
Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. Blood. 2000 Academic Article GET IT
Times cited: 22
Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Current opinion in hematology. 2000 Information Resource GET IT
Times cited: 21
Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Experimental cell research. 2000 Academic Article GET IT
Times cited: 70
Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000 Academic Article GET IT
Times cited: 469
Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood. 2000 Academic Article GET IT
Times cited: 51
Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Molecular biotechnology. 2000 Academic Article GET IT
Times cited: 19
The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. Journal of virology. 2000 Academic Article GET IT
Times cited: 179
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nature biotechnology. 2000 Academic Article GET IT
Times cited: 140
Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. Journal of immunology (Baltimore, Md. : 1950). 2000 Academic Article GET IT
Times cited: 58
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (New York, N.Y.). 2000 Information Resource GET IT
Times cited: 348
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 95
Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection. The journal of gene medicine. 1999 Academic Article GET IT
Times cited: 33
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 212
Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 108
Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line. Cancer immunology, immunotherapy : CII. 1999 Academic Article GET IT
Times cited: 5
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. The Journal of experimental medicine. 1998 Academic Article GET IT
Times cited: 266
Adenovirus facilitated infection of human cells with ecotropic retrovirus. Gene therapy. 1998 Academic Article GET IT
Times cited: 18
Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. Seminars in hematology. 1998 Information Resource GET IT
Times cited: 102
Involvement of interleukin-3 in delayed-type hypersensitivity. Blood. 1998 Academic Article GET IT
Times cited: 61
Efficient retroviral infection of human cells utilising an adenoviral vector expressing the ecotropic receptor. Advances in experimental medicine and biology. 1998 Academic Article GET IT
Times cited: 3
Immuno gene therapy comes into its own. Gene therapy. 1997 Editorial Article GET IT
Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector. Leukemia research. 1997 Academic Article GET IT
Times cited: 10
The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene therapy. 1997 Academic Article GET IT
Times cited: 52
Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood. 1997 Academic Article GET IT
Times cited: 70
Tetracycline-mediated suppression of gene expression with a new dicistronic retroviral vector. Molecules and cells. 1997 Academic Article GET IT
Times cited: 4
Genetic treatment of the haemoglobinopathies: recombinations and new combinations. British journal of haematology. 1997 Information Resource GET IT
Times cited: 23
Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood. 1997 Academic Article GET IT
Times cited: 143
Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. Methods in molecular medicine. 1997 Academic Article GET IT
Methods for the construction of retroviral vectors and the generation of high-titer producers. Methods in molecular medicine. 1997 Academic Article GET IT
Active site-directed double mutants of dihydrofolate reductase. Cancer research. 1996 Academic Article GET IT
Times cited: 50
Gene therapy--the challenge for the future. Annals of oncology : official journal of the European Society for Medical Oncology. 1996 Academic Article GET IT
Times cited: 1
Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proceedings of the National Academy of Sciences of the United States of America. 1995 Academic Article GET IT
Times cited: 185
Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 1994 Academic Article GET IT
Times cited: 328
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science (New York, N.Y.). 1994 Academic Article GET IT
Times cited: 709
Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer research. 1994 Academic Article GET IT
Times cited: 47
Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. Journal of immunology (Baltimore, Md. : 1950). 1993 Academic Article GET IT
Times cited: 179
Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. Journal of autoimmunity. 1990 Academic Article GET IT
Times cited: 80
Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes. 1990 Academic Article GET IT
Times cited: 260
Host natural suppressor activity regulates hemopoietic engraftment kinetics in antibody-conditioned recipient mice. Journal of immunology (Baltimore, Md. : 1950). 1990 Academic Article GET IT
Times cited: 11
Delayed activation of quiescent donor hematopoietic stem cells in the host marrow cavity by anti-host monoclonal antibody. Blood. 1989 Academic Article GET IT
Times cited: 9
The role of natural suppressor and natural killer activities in resistance to hemopoietic transplantation in unirradiated hosts. Journal of immunology (Baltimore, Md. : 1950). 1989 Academic Article GET IT
Times cited: 10
The role of natural suppression in mediating resistance to antibody-facilitated bone marrow engraftment. Transplantation proceedings. 1989 Academic Article GET IT
Times cited: 1

more ...

less ...

Background

education and training

Ph.D., University of Alberta (Canada) 1989
M.D., University of Paris Medical School (France) 1984

Contact

full name

Michel Sadelain

VIVO Weill Cornell Medical College

Michel Sadelain Associate Professor of Immunology in Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name